New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 20, 2014
05:27 EDTSHPG, ABBVShire confirms rejection of AbbVie proposal
Shire (SHPG) notes the announcement made by AbbVie (ABBV) and confirms that on May 30, Shire received an unsolicited and highly conditional proposal from AbbVie regarding a possible cash and share offer for Shire. This Proposal has been rejected. The Proposal comprised 20.44 in cash and 0.7988 AbbVie shares per Shire share. The Proposal involved a new U.S. listed holding company with a UK tax domicile. Based on AbbVie's 30 day volume weighted average share price of $54.10, the Proposal represents a value of GBP 46.11 per Shire share. Following this meeting, the board of Shire decided unanimously to reject the Proposal on the basis that it fundamentally undervalued the company and its prospects. The board also had concerns regarding the execution risks associated with the proposed inversion structure, as AbbVie would redomicile in the UK for tax purposes.
News For SHPG;ABBV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
17:46 EDTABBVAbbVie confirms FDA approval of VIEKIRA PAK
Subscribe for More Information
14:40 EDTABBVFDA approves Viekira Pak to treat hepatitis C
Subscribe for More Information
11:02 EDTABBVAbbVie receives orphan status for brain metastases treatment
The FDA granted AbbVie orphan status for veliparib, its treatment of brain metastases when used in combination with DNA-damaging agents.
December 17, 2014
11:28 EDTSHPGNPS Pharmaceuticals calls active on Shire considering bid report
Subscribe for More Information
11:13 EDTSHPGShire considering bid for NPS Pharmaceuticals, Bloomberg reports
Subscribe for More Information
10:49 EDTSHPGNPS Pharmaceuticals jumps 12%, halted after report of potential Shire bid
Shire (SHPG) has NPS Pharmaceuticals (NPSP) on the top of its list of potential takeover targets, but is also said to be considering other targets, according to Bloomberg.
10:47 EDTSHPGNPS Pharmaceuticals said to be on top of Shire takeover list, Bloommberg says
Subscribe for More Information
10:47 EDTSHPGNPS halted for volatility after Bloomberg says Shire considers bid
Subscribe for More Information
December 11, 2014
10:13 EDTABBVOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: ARIAD (ARIA) downgraded at Credit Suisse... AbbVie (ABBV) downgraded to Equal Weight from Overweight at Morgan Stanley... Aimco (AIV) downgraded to Hold from Buy at KeyBanc... Anglo American (AAUKY) downgraded to Underperform from Neutral at Exane BNP Paribas... Approach Resources (AREX) downgraded at Sterne Agee... CommVault (CVLT) downgraded to Neutral from Outperform at Macquarie... Fifth Street Senior (FSFR) downgraded to Perform from Outperform at Oppenheimer... Harmonic (HLIT) downgraded to Neutral from Buy at Sidoti... Macerich (MAC) downgraded to Hold from Buy at Deutsche Bank... Newell Rubbermaid (NWL) downgraded to Outperform from Strong Buy at Raymond James... Olin Corp. (OLN) downgraded at Longbow... Penn West (PWE) downgraded to Underperform from Neutral at BofA/Merrill... Prudential plc (PUK) downgraded to Neutral from Buy at Nomura... Semiconductor Manufacturing (SMI) downgraded to Hold from Buy at Jefferies... Suncor (SU) downgraded to Neutral from Buy at BofA/Merrill... Talisman Energy (TLM) downgraded to Underperform from Neutral at BofA/Merrill... Thompson Creek (TC) downgraded to Hold from Buy at Deutsche Bank... Toll Brothers (TOL) downgraded to Underperform from Sector Perform at RBC Capital... Travelers (TRV) downgraded to Neutral from Buy at UBS... United Therapeutics (UTHR) downgraded at Credit Suisse... Vera Bradley (VRA) downgraded to Underperform from Neutral at Sterne Agee.
08:57 EDTSHPGLeerink major pharma & biotech analysts hold analyst/industry conference call
Subscribe for More Information
08:34 EDTABBVAbbVie downgraded at Morgan Stanley
Subscribe for More Information
07:54 EDTABBVGilead shares poised to continue to advance, says RBC Capital
Subscribe for More Information
06:29 EDTSHPG, ABBVShire CEO sees no immediate need to spend break-up fee, Reuters reports
Subscribe for More Information
06:20 EDTABBVAbbVie downgraded to Equal Weight from Overweight at Morgan Stanley
December 9, 2014
12:22 EDTSHPGPiper Jaffray biopharm analyst holds an analyst/industry conference call
Senior Research Analyst Schimmer, along with Biopharmaceuticals Analyst Breazzano, discuss gene therapy for hemophilia on an Analyst/Industry conference call to be held on December 11 at 10 am.
10:23 EDTSHPGOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
07:44 EDTABBVAmerican Association for Cancer Research to hold a symposium
Subscribe for More Information
05:38 EDTSHPGShire downgraded to Neutral from Buy at BofA/Merrill
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use